ATM encodes a kinase that acts as a master controller of the cellular DNA damage response: it detects double-strand breaks and coordinates DNA repair, cell cycle arrest, or apoptosis through downstream targets including p53, BRCA1, and CHK2. Loss-of-function mutations in both copies of ATM cause ataxia telangiectasia, an autosomal recessive disorder characterized by neurological problems, immune deficiency, and cancer predisposition. ATM functions as a tumor suppressor: individuals with ataxia telangiectasia are prone to childhood lymphomas, leukemias, and breast cancer, while carriers of a single altered copy have increased risk of breast, pancreatic, prostate, and other cancers. Somatic ATM mutations also occur in lymphoid malignancies and solid tumors, and ATM-deficient cancers are often especially sensitive to DNA-damaging treatments.

ATM is a tumor suppressor whose loss-of-function mutations cause ataxia telangiectasia and predispose carriers to breast, pancreatic, and other cancers, so variants here are directly relevant to hereditary cancer risk. This p.Ile280Val missense change is a VUS: it is extremely rare in the population yet computationally benign-leaning, so its impact on ATM's DNA-damage-response function remains unresolved and it neither confirms nor excludes disease risk.